supports the development of mature synapses and regulates cellular function via several regulatory pathways. IGF-1 has been used to promote growth in children with short stature due to IGF-1 deficiency or growth hormone (GH) deficiency, but only for a limited amount of time. Animal models of PMS have shown the rescue of neurological and behavioral functions following treatment with IGF-1. We aim to explore the impact of IGF-1 treatment on the metabolic response to a large panel of metabolites and effectors to determine if IGF-1 can rescue the abnormal metabolic pathways present in individuals with PMS.
Methods: Previous experiments employing the Biolog Phenotype Mammalian Microarrays (PM-Ms) assessed the metabolic profile of lymphoblastoid cell lines (LCLs) from individuals with PMS: results from these experiments were analyzed to identify five subjects who were high metabolizers of IGF-1 and five that were low metabolizers. The Biolog data for those ten people were evaluated across all eight PM-M Biolog plates to determine which plates had the greatest differences when compared to a group of 50 controls.
Results: Ten abnormal metabolic responders were identified from a PMS cohort of 54 individuals. Five controls were randomly selected from a cohort of 50 people. Four Biolog PM-M plates were identified as plates of interest with the effectors being carbon energy sources, hormones, growth factors and cytokines (PM-M1, and PM-M6 to M8). The LCLs of these ten subjects with PMS showing abnormal metabolic response to IGF-1 will be utilized in our pilot study aimed at addressing the efficacy of IGF-1 treatment with the potential to identify ideal candidates for the treatment.
Conclusion: The 15 selected LCLs will be used to determine the effect IGF-1 has on the differing metabolic profile of the high, low, and average responders.

https://doi.org/10.1016/j.gim.2022.01.040

eP003

Novel use of IL-1 inhibition via canakinumab in two patients with lysinuric protein intolerance and immune dysregulation

Thomas Michniacki[1] and Elizabeth Ames[1]

[1]*University of Michigan Health System*

Background: Lysinuric protein intolerance (LPI) is an autosomal recessive condition caused by the deficiency of the light subunit of the y^+ LAT1 transporter and biallelic pathogenic variants in the *SLC7A7* gene. The y^+ LAT1 transporter is most heavily expressed by renal epithelial cells and the intestinal basolateral membrane. Deficiency of this transporter in these tissues results in decreased absorption and reuptake of the cationic amino acids: lysine, ornithine, and arginine. Decreased arginine and ornithine results in secondary urea cycle dysfunction that is associated with some of the clinical features associated with LPI including hyperammonemia, protein avoidance, and poor growth. However, LPI has multiple clinical features not commonly seen in primary urea cycle disorders including osteoporosis, renal disease, interstitial lung disease, and immune dysfunction including hemophagocytic lymphohistiocytosis (HLH). In vitro studies of *SLC7A7*-deficient monocyte and macrophage cell lines suggest that some of the immune phenotype is driven by high levels of pro-inflammatory cytokines TNF-alpha and IL-1beta.
Case presentation: The proband is an 11-year-old female who was seen in general genetics clinic for evaluation of recurrent fractures and concern for osteogenesis imperfecta. She had a history of 5 lifetime fractures that were notable for prolonged healing requiring casts/braces for longer than expected. On physical exam, she had short stature and hepatomegaly. A skeletal survey was obtained that showed significant demineralization, healed/healing prior fractures, multiple compression fractures of the thoracic spine, and interstitial lung disease. The combination of demineralization and interstitial lung disease raised the question of LPI. Subsequent screening labs were performed and notable for elevated transaminases, LDH, ferritin, and zinc. Hematologic labs were notable for mild neutropenia (absolute neutrophil count 1000 cells/microliter), but normal platelets, hemoglobin, and fibrinogen. LPI was biochemically confirmed with plasma amino acids (elevated glutamine, decreased ornithine and lysine), urine amino acids (elevated lysine, arginine, and ornithine), and urine organic acids (orotic acid present). Molecular testing identified two pathogenic variants in *SLC7A7* (NM_001126106.2:c.426_434del, p.Tyr142* and c.1263_1269del, p.Ile422Serfs*95), confirming the diagnosis of LPI. After diagnosis, the proband was referred to several specialists including Immunohematology, Endocrinology, Nephrology, Pulmonology, and Hepatology for further evaluation. Additional labs ordered by Immunohematology were consistent with a smoldering HLH picture, where the patient was asymptomatic but had laboratory findings consistent with severe immune dysregulation: elevated ferritin, slightly reduced CD107a, elevated sCD163 and elevations in various cytokines, including sIL2R. Interestingly, ESR and CRP were normal.
The proband's 12-year-old full sister was noted to have similar features (short stature, multiple fractures, and protein intolerance). Initial labs obtained as part of screening for LPI when she was asymptomatic were notable for an elevated ferritin of 1447 mg/mL (normal 6-155), elevated triglycerides (450 mg/dL, normal < 90), elevated transaminases (AST 247 IU/L, ALT 149 IU/L), CBCD with mild thrombocytopenia (126,000 cells/microliter), mild neutropenia (ANC 1100 cells/μL) and normal hemoglobin and fibrinogen. Subsequent molecular testing confirmed the diagnosis of LPI in this patient as well. Her imaging was notable for hepatic steatosis and splenomegaly. A chest CT showed mild interlobular septal thickening bilaterally, likely representing early manifestation of interstitial lung disease. During her evaluation with Immunohematology, she also had evidence of smoldering chronic inflammation with laboratory features of HLH (elevated ferritin, increased S100A proteins, reduced CD107a, elevated sCD163, cytopenias and increased cytokines).
Following the LPI diagnosis, both sisters were started on a protein-restricted diet (although this was similar to their protein intake prior to diagnosis). They were also started on glycerol phenylbutyrate and supplementation of lysine, citrulline, and carnitine. Due to numerous fractures, both children were started on zoledronic acid infusions every 6 months. Based on concerns for smoldering HLH and rapidly progressive lung disease, they were started on IL-1 inhibition via canakinumab 2 mg/kg every 4 weeks. In the 6 months since canakinumab initiation, both sisters have had reductions in their ferritin levels. The older sister with higher ferritin at diagnosis, also had more dramatic decreases in her transaminases. Both sisters continue to have stable, mild neutropenia and remain asymptomatic from a HLH perspective.
Conclusion: We present two patients with LPI to highlight a new treatment modality for this condition using the IL-1 antagonist canakinumab. In the 6 months since starting this treatment, their inflammatory markers have improved. How this may alter the overall trajectory of LPI including the insidious progression of lung disease is unknown but warrants further consideration.

https://doi.org/10.1016/j.gim.2022.01.041